重庆三圣实业股份有限公司 2022 年第三季度报告 证券代码：002742 证券简称：ST 三圣 公告编号：2022-81 重庆三圣实业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 重庆三圣实业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 504,420,228.14 | -11.41% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥962,826,665.42, a decrease of 21.10% compared to ¥1,220,255,739.91 in the same period last year[24]. - The net loss attributable to shareholders was ¥40,738,537.48, representing a decline of 154.51% from a loss of ¥16,006,931.98 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was ¥-35,750,132.27, which is a 21.11% increase in loss compared to ¥-29,517,672.30 last year[24]. - The basic earnings per share were ¥-0.0943, down 154.18% from ¥-0.0371 in the same period last year[24]. - The company reported a significant increase in investment, with ¥81,061,612.29 in the reporting period, a change of 2,528.22% compared to the previous year[56]. - The company reported a total comprehensive loss of CNY 27,882,149.96 for the first half of 2022, compared to a loss of CNY 76,542,891.78 in the same period of 2021[163]. - The net profit for the first half of 2022 was a loss of CNY 27,882,149.96, compared to a loss of CNY 76,542,891.78 in the same period of 2021, indicating a narrowing of losses[163]. - The company reported a net loss of 24.1161 million yuan for 2022, indicating significant financial challenges[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,111,061,163.44, a decrease of 6.84% from ¥4,413,070,944.02 at the end of the previous year[24]. - The net assets attributable to shareholders decreased by 3.54% to ¥1,081,189,903.37 from ¥1,120,844,682.25 at the end of the previous year[24]. - The total liabilities decreased to ¥2,848,680,833.70 from ¥3,099,798,674.40 at the beginning of the year[151]. - The company reported a total debt of 65,000 million as of June 20, 2022, with a significant portion maturing on December 1, 2022[116]. - The company has a total approved guarantee amount of CNY 546.5 million during the reporting period, with actual guarantees amounting to CNY 41.8 million[119]. Cash Flow - The net cash flow from operating activities was ¥60,959,395.02, a slight decrease of 2.48% compared to ¥62,508,850.13 in the same period last year[24]. - The cash and cash equivalents net increase was ¥28.51 million, a decline of 64.69% compared to the previous year[46]. - The ending balance of cash and cash equivalents was ¥77,821,997.33, down 50.5% from ¥156,873,058.89 at the end of the first half of 2021[165]. - Total cash inflow from operating activities decreased to ¥843,293,629.32, down 31.7% from ¥1,235,645,619.69 in the first half of 2021[164]. - Cash outflow from operating activities also decreased to ¥782,334,234.30, a reduction of 33.3% compared to ¥1,173,136,769.56 in the previous year[164]. Business Segments - The company operates in two main business segments: construction materials and pharmaceuticals, with a leading position in ready-mixed concrete and additives in the construction materials sector[32]. - The pharmaceutical segment includes intermediates and active pharmaceutical ingredients, with key products such as procaine hydrochloride and cephalosporin intermediates, which hold a leading market position[33]. - The construction materials segment's revenue is primarily derived from ready-mixed concrete, concentrated in the Chongqing region, benefiting from the city's strategic economic position[35]. - The pharmaceutical manufacturing segment achieved profitability, contributing positively to the company's overall performance through enhanced management and market expansion efforts[38]. Market Conditions and Strategies - The company reported a loss in its main business due to severe market shocks in the construction materials sector, exacerbated by cash flow issues and strict environmental policies[37]. - The construction materials industry is closely tied to macroeconomic conditions, with demand expected to remain high due to ongoing infrastructure investments in Chongqing[36]. - The company has implemented various measures to mitigate losses, including internal management improvements and product price adjustments[38]. - The company plans to enhance its market expansion and diversification strategies to mitigate regional sales concentration risks[66]. - The company aims to improve its profitability by optimizing inventory management and enhancing accounts receivable turnover[68]. Environmental Compliance - The company strictly complies with various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[77]. - The wastewater treatment plant operates within the limits of chemical oxygen demand (COD) at less than 100 mg/L and ammonia nitrogen at less than 15 mg/L[79]. - The company has implemented measures to ensure that emissions of particulate matter are below 30 mg/m3 and sulfuric acid mist below 5 mg/m3[79]. - The company has not reported any instances of exceeding pollution discharge standards[79]. Corporate Governance and Investor Relations - The company adheres to regulations for shareholder meetings, ensuring the rights of minority shareholders are protected through both in-person and online voting options[87]. - The company has established an investor hotline to enhance communication with minority investors, providing timely updates on company developments[87]. - The board secretary is responsible for information disclosure, ensuring compliance with regulatory standards and maintaining transparency with investors[87]. - The company has committed to fulfilling its promises regarding the initial public offering, with ongoing compliance monitored[89]. Future Outlook - The company plans to expand its market presence and invest in new product development in the upcoming quarters[170]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by new product launches and market expansion efforts[170]. - Future guidance indicates a projected revenue growth of 10% for the next half-year, driven by increased demand and market expansion efforts[174].

Financial Performance - The company's operating revenue for Q1 2022 was ¥453,744,979.80, a decrease of 18.46% compared to ¥556,440,760.58 in the same period last year[3]. - The net profit attributable to shareholders was ¥5,242,468.17, down 79.39% from ¥25,432,495.73 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,353,261.68, a decline of 94.58% compared to ¥24,957,499.98 in the previous year[3]. - Net profit for the current period was ¥11,543,202.81, a decline of 64.1% from ¥32,202,374.09 in the previous period[17]. - The total comprehensive income attributable to the parent company was -3,585,025.85 CNY, compared to 14,703,286.67 CNY in the previous period, indicating a significant decline[18]. - The basic and diluted earnings per share were both 0.0121 CNY, a decrease from 0.0589 CNY in the previous period[18]. Cash Flow - The net cash flow from operating activities was -¥22,050,335.26, a significant decrease of 211.90% from ¥19,705,673.55 in the same period last year[3]. - Cash received from the sale of goods and services was 288,579,411.32 CNY, down from 507,096,538.96 CNY in the previous period[20]. - The total cash outflow from operating activities was 429,841,376.98 CNY, down from 640,131,996.11 CNY in the previous period[21]. - The net cash flow from investing activities was -17,120,899.80 CNY, compared to -13,247,263.42 CNY in the previous period, reflecting increased investment outflows[21]. - The net cash flow from financing activities was 26,727,923.35 CNY, compared to -32,900,038.64 CNY in the previous period, indicating a recovery in financing[22]. - The total cash inflow from financing activities was 199,100,000.00 CNY, an increase from 124,700,000.00 CNY in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,238,393,725.92, down 3.96% from ¥4,413,070,944.02 at the end of the previous year[3]. - Current assets totaled ¥1,850,317,112.41, down 9.5% from ¥2,044,517,296.79 at the beginning of the year[12]. - The company's total assets decreased to ¥4,238,393,725.92 from ¥4,413,070,944.02, representing a reduction of 3.95%[14]. - The total liabilities decreased to ¥2,935,849,222.17 from ¥3,099,798,674.40, a decline of 5.3%[14]. - The company's long-term borrowings decreased to ¥196,208,333.13 from ¥268,000,000.00, a reduction of 26.8%[14]. Operational Metrics - The company reported a significant reduction in cash and cash equivalents, with a decrease of 45.81% in monetary funds to ¥97,547,210.36[6]. - The company experienced an 85.38% decrease in receivables financing, totaling ¥6,244,326.62, primarily due to cash payments to suppliers[6]. - Total operating costs amounted to ¥457,827,141.40, down from ¥533,455,565.37, reflecting a reduction of 14.1%[16]. - Research and development expenses were ¥4,898,797.18, down 28.7% from ¥6,875,272.23 in the previous period[17]. - Accounts receivable decreased to ¥1,132,709,492.32 from ¥1,182,940,925.41, a reduction of 4.2%[12].

Financial Performance - The company reported a significant increase in revenue, with a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[1]. - The company's operating revenue for 2021 was ¥2,489,145,222.21, a decrease of 2.37% compared to ¥2,549,509,857.65 in 2020[21]. - The net profit attributable to shareholders for 2021 was -¥333,437,976.48, representing a decline of 554.05% from a profit of ¥73,436,772.60 in 2020[21]. - The company's total revenue for 2021 was ¥2,489,145,222.21, a decrease of 2.37% compared to ¥2,549,509,857.65 in 2020[54]. - The construction materials segment generated revenue of ¥1,583,309,655.22, down 14.38% from ¥1,849,300,071.48 in the previous year, accounting for 63.61% of total revenue[55]. - The pharmaceutical segment achieved revenue of ¥867,146,237.43, an increase of 30.41% from ¥664,916,596.01 in 2020, representing 34.84% of total revenue[55]. - The company reported a significant increase in financial pressure due to tightening liquidity and rising financing costs, impacting overall profitability[50]. Market and Growth Strategies - The company has outlined a future outlook with a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[1]. - The company is positioned as a major player in the global chemical raw material and pharmaceutical formulation production markets, with China accounting for 20% of the global pharmaceutical sales market[39]. - The company has implemented an internationalization strategy, with overseas projects beginning to yield results[41]. - The company is actively pursuing international expansion, particularly in Africa, to diversify its market presence and reduce business risks[89]. Research and Development - Investment in new product development increased by 25%, focusing on innovative materials and technologies in the construction sector[1]. - The company has invested in R&D, establishing a pharmaceutical research center that supports new drug development and has a complete drug R&D system[44]. - The company filed 11 patent applications and participated in the formulation of 8 national industry standards during the reporting period, enhancing its innovation capabilities[51]. - The company aims to strengthen its research and development capabilities, particularly in extending product life cycles and promoting original research[88]. Corporate Governance and Internal Controls - Internal control deficiencies were identified, with the actual controller having significant influence over the company's operations, which may pose risks[1]. - The company has committed to enhancing its corporate governance practices to address identified risks and improve transparency[1]. - The company reported a significant internal control deficiency related to the misuse of funds by major shareholders, with corrective measures planned for implementation by April 18, 2022[128]. - The company plans to strengthen internal control management and improve the internal audit department's functions to prevent future issues[129]. - The company has implemented measures to prevent non-operating fund occupation by major shareholders and related parties, including strengthening management systems and internal controls[135]. Environmental and Social Responsibility - The company has initiated comprehensive environmental remediation efforts, including the installation of dust reduction and solid waste disposal equipment, to ensure sustainable operations[51]. - The company has established a self-monitoring plan in compliance with environmental regulations[146]. - The company conducts at least one emergency drill for environmental incidents annually[147]. - The company has implemented a waste classification system, with wastewater categorized into five types for proper treatment[144]. - The company has not conducted any poverty alleviation or rural revitalization work during the reporting period[152]. Legal and Compliance Issues - The accounting firm Tianjian has issued a non-standard audit report, highlighting significant uncertainties related to the company's ongoing operations[162]. - The company has not reported any environmental accidents during the reporting period[149]. - The company is involved in ongoing litigation with amounts exceeding 1 billion, indicating potential future cash inflows[170]. - The company has successfully resolved disputes with several construction firms, resulting in favorable outcomes and payments received[169]. Leadership and Management Changes - The company experienced changes in its board of directors, with multiple resignations including the chairman and general manager on August 25, 2021[101]. - The company appointed Xiang Liping as the chairman and general manager on November 26, 2021[102]. - The company has been actively adjusting its management team to enhance operational efficiency[101]. - The management team includes professionals with backgrounds in finance, engineering, and pharmaceuticals, indicating a diverse skill set[105][106]. Employee and Shareholder Engagement - The company has established a performance-oriented compensation system to motivate employees, which includes base salary, performance bonuses, and incentives[123]. - The company ensures shareholder rights by providing both in-person and online voting options for shareholders[150]. - The company maintains investor relations through regular disclosures and a dedicated investor hotline[151]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to 358.88 million CNY[114].

证券代码：002742 证券简称：三圣股份 公告编号：2021-82 号 重庆三圣实业股份有限公司 关于参加重庆辖区上市公司 2021 年投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为推动辖区上市公司做好投资者关系管理工作，促进上市公司完善公司治 理，进一步提高上市公司质量，在重庆证监局指导下，重庆上市公司协会联合上 证所信息网络有限公司、深圳市全景网络有限公司举办辖区上市公司2021年投资 者网上集体接待日活动。 活动将于2021年11月25日（星期四）15:00-17:00举行，投资者可以通过"全 景·路演天下"（http://rs.p5w.net）进入本公司互动平台参与互动交流。 届时，公司相关高管人员将参加本次活动，通过网络在线交流形式，就投资 者所关心的问题，与投资者进行"一对多"形式的在线沟通与交流。欢迎广大投 资者踊跃参与！ 特此公告。 重庆三圣实业股份有限公司董事会 2021 年 11 月 19 日 ...

Financial Performance - The company's revenue for Q3 2021 was ¥569,396,259.96, a decrease of 19.67% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥26,937,583.85, representing a significant decline of 1,365.06% year-on-year[3]. - The basic earnings per share were -¥0.0623, reflecting a decline of 1,346.17% compared to the same period last year[3]. - Total operating revenue for Q3 2021 was CNY 1,789,651,999.87, a decrease of 2.7% compared to CNY 1,839,114,496.46 in the same period last year[22]. - Net profit for Q3 2021 was a loss of CNY 20,787,859.47, compared to a profit of CNY 67,775,680.76 in Q3 2020, marking a significant decline[23]. - The company reported a basic and diluted earnings per share of -0.0994, a decline from 0.1107 in the same quarter last year[24]. - Other comprehensive income after tax was a loss of CNY 57,255,975.16, compared to a loss of CNY 69,867,194.08 in the previous year[23]. Cash Flow and Assets - The net cash flow from operating activities was -¥25,165,735.87, down 66.62% year-to-date[3]. - The cash flow from operating activities was CNY 1,481,304,876.44, compared to CNY 1,674,913,996.86 in the previous period[26]. - The net cash flow from operating activities for Q3 2021 was -25,165,735.87 CNY, an improvement from -75,391,345.76 CNY in Q3 2020[27]. - Total assets at the end of the reporting period were ¥4,318,229,013.65, a decrease of 11.47% from the previous year[4]. - The company's total assets decreased to CNY 4,318,229,013.65 from CNY 4,877,608,615.06, reflecting a reduction of approximately 11.5%[20]. - The ending balance of cash and cash equivalents was 32,937,767.53 CNY, a decrease from 93,973,708.20 CNY at the end of Q3 2020[28]. - The company experienced a 32.82% decrease in cash and cash equivalents, totaling ¥232,230,745.89, primarily due to concentrated payments during the Spring Festival[8]. - As of September 30, 2021, the company's cash and cash equivalents decreased to ¥232,230,745.89 from ¥345,678,809.61 at the end of 2020, representing a decline of approximately 32.7%[18]. Liabilities and Equity - Total liabilities decreased to CNY 2,649,485,900.54, down from CNY 3,121,460,928.61, indicating a reduction of about 15.1%[20]. - The total equity attributable to shareholders decreased by 5.48% to ¥1,432,837,177.18[4]. - The company has pledged 100% of its equity in Liaoyuan Baikang Pharmaceutical Co., Ltd. for loans totaling ¥66,961,511.27, with the last loan due on November 22, 2021[15]. - The company has also pledged 72% of its equity in Chongqing Chunrui Pharmaceutical Chemical Co., Ltd. for loans totaling ¥409,000,000.00, with the last loan due on May 20, 2023[15]. - The first major shareholder, Mr. Pan Xianwen, has pledged 165,934,132 shares, which is 97.69% of his holdings, and 35,036,472 shares are frozen, accounting for 20.63% of his total shares[14]. - The actual controller and his associates have cumulatively reduced their holdings by 78,197,572 shares, which is 18.10% of the total share capital[14]. Operational Changes and Future Outlook - The company expects to obtain the gypsum mining license and resume mining operations by the end of 2021, following the approval from the Chongqing Municipal Government[13]. - The company is actively communicating with government departments to restore its gypsum mining rights, which have been suspended since July 2018 due to regulatory restrictions[12]. - The company has undergone changes in its board of directors and supervisory board, with several resignations and new appointments made in September 2021[14]. Expenses - The company reported a significant increase in sales expenses, which rose by 54.95% to ¥18,894,744.14, aimed at maintaining sales volume[8]. - Total operating costs increased to CNY 1,842,094,776.80, up 4.2% from CNY 1,768,551,127.11 year-on-year[22]. - Research and development expenses for the quarter were CNY 20,996,221.29, slightly down from CNY 21,867,690.38 year-on-year[22]. Investment Activities - Cash inflow from investment activities was 239,940,174.00 CNY, significantly higher than 15,401,820.00 CNY in the same period last year[27]. - The net cash flow from investment activities was 77,789,019.63 CNY, compared to -64,306,350.45 CNY in Q3 2020[27].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,220,255,739.91, representing a 7.96% increase compared to CNY 1,130,293,196.84 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 16,006,931.98, a decrease of 135.05% from a profit of CNY 45,671,832.08 in the previous year[21]. - The basic earnings per share were CNY -0.0371, a decline of 135.10% compared to CNY 0.1057 in the same period last year[21]. - The net cash flow from operating activities was CNY 62,508,850.13, a significant improvement of 290.48% compared to a negative cash flow of CNY 32,815,770.63 in the same period last year[21]. - The total operating revenue for the first half of 2021 was CNY 1,220,255,739.91, an increase of 8.0% compared to CNY 1,130,293,196.84 in the same period of 2020[155]. - The net profit for the first half of 2021 was CNY 2,352,505.50, a significant decrease from CNY 57,265,640.15 in the first half of 2020[156]. - Comprehensive income totalled CNY -37,454,033.29, contrasting with CNY 35,289,131.21 in the first half of 2020[156]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,596,000,529.31, down 5.77% from CNY 4,877,608,615.06 at the end of the previous year[21]. - The total liabilities at the end of the reporting period were reported at 478,794,000 CNY, which is a decrease of 44,089,000 CNY compared to the previous period[171]. - The total equity decreased from CNY 1,756,147,686.45 to CNY 1,718,902,494.02, a decline of about 2.1%[149]. - The company's total assets at the end of the current period amounted to CNY 9,435.20 million[182]. Business Segments - The company operates in two main business segments: construction materials and pharmaceuticals, with construction materials including ready-mixed concrete, water-reducing agents, and expansion agents[29]. - The pharmaceutical segment includes intermediates, raw materials, and formulation products, with key products like paracetamol and levofloxacin, contributing to a strong market position[30]. - The construction materials segment faced significant challenges, resulting in a decline in performance due to insufficient construction activity and rising raw material costs, leading to a notable decrease in profit margins[34]. - The pharmaceutical segment achieved profitability through diversified business models and effective management, benefiting from a comprehensive industry layout[35]. Cash Flow and Investments - The net cash flow from investing activities also saw a positive shift, increasing by 120.47% to CNY 84,927,085.72, attributed to the disposal of land and repayments from related parties[42]. - The total investment amount for the reporting period was CNY 3,084,280.93, a significant decrease of 95.62% compared to CNY 70,425,131.06 in the same period last year[52]. - The company made a major equity investment of CNY 80,000,000, acquiring an 80% stake in a project focused on resource recycling in the construction materials industry[52]. Environmental Performance - The company reported a total nitrogen discharge of 752.9 tons, with ammonia nitrogen levels at 60.23 tons, exceeding the standard limits[79]. - The chemical oxygen demand (COD) was recorded at 3.28 tons per annum, indicating compliance with wastewater discharge standards[80]. - The company achieved a reduction in nitrogen oxides emissions to 0.494 tons, aligning with environmental regulations[79]. - The company has implemented new wastewater treatment technologies, resulting in a significant decrease in overall pollutant emissions[80]. Shareholder Information - As of June 30, 2021, the largest shareholder, Mr. Pan Xianwen, holds 169,865,543 shares, representing 39.32% of the total shares, with 97.69% of his shares pledged[125]. - The second largest shareholder, Ms. Zhou Ting'e, holds 31,223,816 shares (7.23% of total shares), with 83.97% of her shares pledged[125]. - The company has pledged 100% of its 72% stake in Chongqing Chunrui Pharmaceutical Chemical Co., Ltd. for a loan of CNY 409 million, due by May 20, 2023[126]. Risk Management - The company faces risks from macroeconomic fluctuations, particularly in the construction and real estate sectors, which could adversely affect cash flow and operations[64]. - Raw material costs account for over 60% of total costs, and price volatility could significantly impact profitability if not managed effectively[65]. - The company plans to diversify and internationalize its operations to mitigate risks associated with regional market concentration[65]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[171]. - The management expressed optimism about future growth despite current challenges in the market[171]. - The company is considering potential mergers and acquisitions to strengthen its market position[171].

Financial Performance - The company's operating revenue for 2020 was ¥2,549,509,857.65, a decrease of 19.83% compared to ¥3,180,117,049.92 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥73,436,772.60, down 41.17% from ¥124,835,098.47 in 2019[16] - The net profit after deducting non-recurring gains and losses was ¥51,631,697.38, a decline of 55.40% from ¥115,756,564.29 in 2019[16] - The basic earnings per share for 2020 was ¥0.1700, a decrease of 41.18% compared to ¥0.2890 in 2019[16] - The total assets at the end of 2020 were ¥4,877,608,615.06, a decrease of 2.94% from ¥5,025,238,817.68 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,515,966,359.02, down 2.49% from ¥1,554,689,593.61 at the end of 2019[16] - The net cash flow from operating activities was ¥140,899,447.36, a decrease of 8.90% from ¥154,662,019.19 in 2019[16] - The weighted average return on net assets for 2020 was 4.79%, down from 8.18% in 2019[16] Revenue Segmentation - The construction materials segment generated revenue of ¥1,849,300,071.48, down 24.56% year-on-year, primarily due to market instability and increased environmental pressures[41] - The pharmaceutical manufacturing segment, boosted by the launch of the second phase of Baikang Pharmaceutical and the operational scale-up of Ethiopia San Sheng Pharmaceutical, reported revenue of ¥664,916,596.01, a decrease of 4.67% year-on-year[42] - The company's total operating revenue for Q4 2020 was approximately ¥710.40 million, showing a steady increase from previous quarters[20] - The net profit attributable to shareholders for Q4 2020 was approximately ¥25.64 million, with a notable increase compared to Q3 2020[20] - The net cash flow from operating activities in Q4 2020 was approximately ¥216.29 million, indicating a strong recovery from negative cash flow in Q2 and Q3[20] Operational Strategies - The company has implemented an order-based production model for non-standard products, ensuring production aligns with market demand[27] - The company has formed a dual-driven model of "construction materials + pharmaceutical manufacturing," effectively diversifying operational risks[33] - The company is focusing on technological innovation and refined management to mitigate the impact of raw material price volatility on profitability[86] - The company plans to enhance its information technology infrastructure to support data-driven management and decision-making processes[44] - The company aims to enhance its market expansion and diversification strategies to mitigate risks associated with concentrated sales in the Chongqing area[85] Investment and Assets - The company's fixed assets in construction projects increased by 32.07% year-on-year, primarily due to the expansion of the green circular construction materials industry base project[31] - The total investment during the reporting period was ¥249,867,473, a significant decrease of 45.58% compared to the previous year[68] - The company has acquired mining rights for limestone in Hohhot District to secure a stable supply of raw materials and reduce production costs[43] Environmental and Regulatory Compliance - The company strictly adheres to various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[139] - The company has implemented a comprehensive pollution control system, including bag filters and electrostatic precipitators at each discharge outlet, ensuring compliance with environmental standards[144] - The company has established a dedicated team for water quality analysis during the wastewater treatment process to ensure compliance with treatment standards[144] - The company has installed desulfurization and dust removal devices in the boiler flue gas system to reduce emissions of sulfur dioxide and particulate matter[144] Shareholder and Governance - The company will not implement profit distribution or capital reserve transfers for the 2020 fiscal year, with retained earnings carried forward[94] - The company has made commitments to small and medium shareholders, which have been fulfilled on time[104] - The annual shareholders' meeting had a participation rate of 64.62% on May 6, 2020[192] - The company maintained shareholder rights by legally convening shareholder meetings[135] Research and Development - The company obtained 31 patent certificates during the reporting period, enhancing its core competitiveness through technological innovation[43] - The company has established a complete drug research and development system, focusing on antibiotics, digestive, respiratory, endocrine, and cardiovascular medications[35] - Research and development expenses decreased by 6.67% to ¥31,825,239.25, while the number of R&D personnel increased by 28.57% to 108[60] Risks and Challenges - The company has faced risks related to its ongoing operations, which are detailed in the report[4] - The construction materials industry in China is closely tied to macroeconomic conditions, with significant growth potential driven by infrastructure investment[28] - The company is actively pursuing international development by investing in Ethiopia for pharmaceutical and new building materials projects, despite potential overseas investment risks[86]

Financial Performance - Revenue for Q1 2021 was CNY 556,440,760.58, an increase of 18.69% compared to CNY 468,819,354.78 in the same period last year[7] - Net profit attributable to shareholders was CNY 25,432,495.73, up 25.10% from CNY 20,330,267.92 year-on-year[7] - Net profit excluding non-recurring items reached CNY 24,957,499.98, representing a significant increase of 51.71% from CNY 16,450,798.42 in the previous year[7] - Basic earnings per share increased to CNY 0.0589, a rise of 25.05% compared to CNY 0.0471 in the same quarter last year[7] - Net profit for Q1 2021 reached CNY 32,202,374.09, compared to CNY 21,286,325.14 in the same period last year, representing a growth of approximately 51.5%[39] - The total comprehensive income attributable to the parent company is CNY 14,703,286.67, compared to CNY -12,139,780.98 in the previous period[43] Assets and Liabilities - Total assets decreased by 7.09% to CNY 4,531,703,975.40 from CNY 4,877,608,615.06 at the end of the previous year[7] - The company's total assets as of March 31, 2021, were CNY 3,819,838,021.29, down from CNY 3,980,672,373.01 at the end of 2020[34] - Total current liabilities decreased to CNY 2,460,642,735.47 from CNY 2,808,795,928.53, a decline of about 12.4%[30] - The company's total liabilities decreased to CNY 2,758,318,624.31 from CNY 3,121,460,928.61, reflecting a reduction of approximately 11.6%[30] - The total equity attributable to shareholders of the parent company was CNY 1,223,982,055.50, down from CNY 1,242,441,477.55 at the end of 2020[35] Cash Flow - Net cash flow from operating activities dropped significantly by 80.05% to CNY 19,705,673.55 from CNY 98,797,339.81 in the previous year[7] - The net cash flow from operating activities is CNY 19,705,673.55, down from CNY 98,797,339.81 in the previous period[47] - Operating cash flow net amount for the current period is ¥27,237,508.11, a decrease of 61.8% compared to ¥71,338,427.53 in the previous period[49] - Total cash inflow from operating activities is ¥648,001,055.42, up 22.5% from ¥528,823,337.77 in the previous period[49] - Cash outflow from operating activities totaled ¥620,763,547.31, an increase of 35.7% compared to ¥457,484,910.24 in the previous period[49] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,406[10] - The largest shareholder, Pan Xianwen, holds 39.50% of the shares, amounting to 170,641,110 shares, with a significant portion pledged[10] - The company did not engage in any share repurchase transactions during the reporting period[11] Research and Development - The company reported a significant increase in research and development expenses to CNY 6,875,272.23 from CNY 4,814,575.42 in the previous period[38] - The company incurred research and development expenses of CNY 4,927,822.92, an increase from CNY 3,137,522.19 in the previous period[42] Compliance and Internal Control - The proportion of non-operating fund occupation at the end of the reporting period was 5.20% of the latest audited net assets[23] - The company plans to strengthen internal control systems and improve fund management processes to prevent non-operating fund occupation[23] - The company aims to enhance the training of key personnel to improve compliance awareness and prevent fund occupation behaviors[23] - The company reported no violations regarding external guarantees during the reporting period[20] - The company has not conducted any research, communication, or interview activities during the reporting period[24] Cash and Cash Equivalents - The company reported a 41.50% decrease in cash and cash equivalents, totaling CNY 202,209,873.70, primarily due to seasonal payments during the Spring Festival[14] - Cash and cash equivalents decreased to CNY 156,147,756.25 from CNY 292,579,908.28 at the end of 2020[32] - The total cash and cash equivalents at the end of the period is CNY 49,651,067.32, down from CNY 81,273,684.02 at the end of the previous period[48] - The ending balance of cash and cash equivalents is ¥14,721,551.72, down 43.2% from ¥25,991,705.66 in the previous period[51]

Financial Performance - The company's operating revenue for 2020 was ¥2,549,509,857.65, a decrease of 19.83% compared to ¥3,180,117,049.92 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥73,436,772.60, down 41.17% from ¥124,835,098.47 in 2019[16] - The net profit after deducting non-recurring gains and losses was ¥51,631,697.38, a decline of 55.40% from ¥115,756,564.29 in 2019[16] - The basic earnings per share for 2020 was ¥0.1700, a decrease of 41.18% compared to ¥0.2890 in 2019[16] - The total assets at the end of 2020 were ¥4,877,608,615.06, a decrease of 2.94% from ¥5,025,238,817.68 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,515,966,359.02, down 2.49% from ¥1,554,689,593.61 at the end of 2019[16] - The net cash flow from operating activities was ¥140,899,447.36, a decrease of 8.90% from ¥154,662,019.19 in 2019[16] - The weighted average return on net assets for 2020 was 4.79%, down from 8.18% in 2019[16] Revenue Segmentation - The construction materials segment generated revenue of approximately ¥1.85 billion, down 24.56% year-on-year, primarily due to market instability and increased environmental pressures[41] - The pharmaceutical manufacturing segment achieved revenue of approximately ¥664.92 million, with a year-on-year decline of 4.67%, indicating a gradual increase in its share of the company's overall business[42] - The construction materials and chemicals segment accounted for 72.54% of total revenue, with a revenue of approximately ¥1.85 billion, down 24.56% year-over-year[48] - The pharmaceutical segment generated approximately ¥664.92 million, representing 26.08% of total revenue, with a decline of 4.67% from the previous year[49] Operational Highlights - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company has faced risks related to its ongoing operations, which are detailed in the report[4] - The company reported non-operating income of approximately ¥21.81 million for 2020, compared to ¥9.08 million in 2019, indicating an increase of 140.5% year-over-year[22] - The company achieved a year-on-year increase of 32.07% in construction projects under construction, primarily due to the expansion of the green circular building materials industry base project in Yubei District[31] Market Position and Strategy - The construction materials industry in China is closely tied to macroeconomic conditions, with significant reliance on fixed asset investment and infrastructure spending, presenting growth opportunities for the company[28] - The company operates primarily in the Chongqing region for its construction materials segment, benefiting from local market conditions and infrastructure investments[28] - The company has established a reliable supply chain system, enhancing its procurement capabilities through various models such as tender procurement and long-term strategic cooperation[27] - The company has a diversified and international development strategy, which effectively mitigates operational risks associated with economic cycles[33] Research and Development - The company has established a research center for concrete additives, focusing on developing high-performance products tailored to customer needs[34] - The company has established a comprehensive drug research and development system, focusing on antibiotics, digestive, respiratory, endocrine, and cardiovascular drugs[35] - The company has made significant investments in overseas projects, with initial results from these investments becoming apparent as international strategies are implemented[30] - The company has a strong technical advantage, supported by a robust research and development framework for concrete additives and pharmaceuticals[33] Environmental and Regulatory Compliance - The company emphasizes sustainable development while considering investor returns, adhering to relevant laws and regulations regarding profit distribution[98] - The company strictly adheres to various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[140] - The company has implemented a comprehensive pollution control system, including bag filters and electrostatic precipitators at each discharge outlet, ensuring compliance with environmental standards[145] - The company has established an automatic online monitoring system for emissions, managed by a qualified third party to ensure compliance[145] Shareholder and Governance - The company maintained shareholder rights by legally convening shareholder meetings[136] - The company has not engaged in any mergers or acquisitions during the reporting period[165] - The management team consists of experienced professionals with backgrounds in finance and pharmaceuticals[174][175] - The company has not reported any new product developments or technological advancements in the current reporting period[165] Employee and Management Structure - The total number of employees in the company is 3,085, with 2,053 in production, 126 in sales, 354 in technical roles, 60 in finance, and 492 in administration[183] - The company has established a training plan to enhance employee skills and management capabilities, focusing on various aspects including occupational skills and safety management[186] - The company has a competitive salary and benefits system, with employee compensation consisting of basic and performance-based wages[185] - The company’s board of directors and senior management have not been granted any stock incentives during the reporting period[182]